Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 200,000 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 200,000 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director directly owned 495,000 shares in the company, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.33 during trading on Monday, hitting $24.30. The stock had a trading volume of 11,579,926 shares, compared to its average volume of 11,860,872. The stock has a market cap of $27.87 billion, a price-to-earnings ratio of -151.88, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The company’s 50 day moving average price is $19.74 and its two-hundred day moving average price is $17.89. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $25.00.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.69 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Phoenix Financial Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. Ion Asset Management Ltd. raised its holdings in Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after buying an additional 2,383,500 shares during the period. Menora Mivtachim Holdings LTD. raised its holdings in Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after buying an additional 9,303,978 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in Teva Pharmaceutical Industries by 13.6% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock worth $658,161,000 after buying an additional 3,896,790 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on TEVA shares. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, UBS Group lifted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus target price of $25.86.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.